

S.B. 78

PHARMACY ACT AMENDMENTS

SENATE FLOOR AMENDMENTS

AMENDMENT 3

MARCH 6, 2013 1:26 PM

Senator **Evan J. Vickers** proposes the following amendments:

1. *Page 2, Line 45:*

45 58-17b-605, as last amended by Laws of Utah 2008, Chapter 205

= **63I-2-258, as last amended by Laws of Utah 2012, Chapters 88 and 369**

2. *Page 17, Lines 510 through 516*

Senate Committee Amendments

2-21-2013:

510 (8) **(a)** A pharmacist or pharmacy intern who substitutes an interchangeable biosimilar
511 product for a prescribed biological product shall:

512 ~~{(a)}~~ **(i)** notify the prescriber in writing ~~§→~~, by fax, telephone, or electronic transmission ~~←§~~

512a of the substitution, as soon as practicable, but not

513 later than three business days after dispensing the interchangeable biosimilar product in place

514 of the prescribed biological product; and

515 ~~{(b)}~~ **(ii)** include the name and manufacturer of the interchangeable biosimilar product

516 substituted.

= **(b) This subsection is repealed on March 31, 2016.**

3. *Page 17, Line 521*

Senate Committee Amendments

2-21-2013:

521 authorized does not constitute evidence of negligence.

= **Section 4. Section 63I-2-258 is amended to read:**

63I-2-258. Repeal dates -- Title 58.

(1) Subsection 58-72-201(1)(b) is repealed July 1, 2014.

= **(2) Subsection 58-17b-606.5(8) is repealed on March 31, 2016.**

Renumber remaining sections accordingly.